Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting
Longeveron Inc. - Class A Common stock (LGVN)
Company Research
Source: GlobeNewswire
Oral presentation highlights findings that patients treated with Lomecel-BTM in ELPIS I, in an open-label follow-on study, experienced 5-year survival after stage 2 Glenn surgery of 100% with none requiring heart transplant; this compared to the largest data set from the Single Ventricle Reconstruction Trial which showed 83% survival, with a 5.2% heart transplantation rateELPIS I met its primary endpoint of safety through 1-year post-treatment, with 100% survival rate, 100% transplant-free and patients maintained expected rate of growth one year after treatmentFindings support cell based therapy as a potential adjunct to HLHS reconstruction surgery to improve clinical benefits and reduce the need for subsequent heart transplantationELPIS II Phase 2b clinical trial is currently ongoing, further evaluating Lomecel-BTM as a potential adjunct therapy for HLHS versus standard of care alone MIAMI, Oct. 27, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotec
Show less
Read more
Impact Snapshot
Event Time:
LGVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LGVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LGVN alerts
High impacting Longeveron Inc. - Class A Common stock news events
Weekly update
A roundup of the hottest topics
LGVN
News
- Longeveron to Present at Biotech Showcase 2025 [Yahoo! Finance]Yahoo! Finance
- Longeveron to Present at Biotech Showcase 2025GlobeNewswire
- Longeveron Inc. (NASDAQ: LGVN) was upgraded by analysts at Roth Capital to a "strong-buy" rating.MarketBeat
- Longeveron Inc. (NASDAQ: LGVN) is now covered by analysts at Roth Mkm. They set a "buy" rating and a $10.00 price target on the stock.MarketBeat
- Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024GlobeNewswire
LGVN
Earnings
- 11/12/24 - Beat
LGVN
Sec Filings
- 12/4/24 - Form 4
- 11/27/24 - Form 144
- 11/14/24 - Form SC
- LGVN's page on the SEC website